SS
HRTX icon

Sunbelt Securities’s Heron Therapeutics HRTX Stock Holding History

Sunbelt Securities’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30 Buy
+37
New +$43 ﹤0.01% 2834

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return

Sunbelt Securities's HRTX Position: Q1 2026 in Review

Sunbelt Securities opened a new position in Heron Therapeutics (HRTX) in Q1 2026: 37 shares worth $30. The stake represents ﹤0.01% of the portfolio and ranks #2834 among its holdings.

167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Sunbelt Securities held 37 shares of Heron Therapeutics worth $30 as of Q1 2026.
  • Heron Therapeutics was a new Sunbelt Securities position in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2834 holding.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.